BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35501995)

  • 21. Effects of exportin 1 on nuclear transport and meiotic resumption in porcine full-grown and growing oocytes.
    Onuma A; Fujioka YA; Fujii W; Sugiura K; Naito K
    Biol Reprod; 2018 Apr; 98(4):501-509. PubMed ID: 29228114
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.
    De Cesare M; Cominetti D; Doldi V; Lopergolo A; Deraco M; Gandellini P; Friedlander S; Landesman Y; Kauffman MG; Shacham S; Pennati M; Zaffaroni N
    Oncotarget; 2015 May; 6(15):13119-32. PubMed ID: 25948791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic targeting of nuclear export and import receptors in cancer and their potential in combination chemotherapy.
    Newell S; van der Watt PJ; Leaner VD
    IUBMB Life; 2024 Jan; 76(1):4-25. PubMed ID: 37623925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. XPO1 Enables Adaptive Regulation of mRNA Export Required for Genotoxic Stress Tolerance in Cancer Cells.
    Marullo R; Rutherford SC; Revuelta MV; Zamponi N; Culjkovic-Kraljacic B; Kotlov N; Di Siervi N; Lara-Garcia J; Allan JN; Ruan J; Furman RR; Chen Z; Shore TB; Phillips AA; Mayer S; Hsu J; van Besien K; Leonard JP; Borden KLB; Inghirami G; Martin P; Cerchietti L
    Cancer Res; 2024 Jan; 84(1):101-117. PubMed ID: 37801604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer.
    Cheng Y; Holloway MP; Nguyen K; McCauley D; Landesman Y; Kauffman MG; Shacham S; Altura RA
    Mol Cancer Ther; 2014 Mar; 13(3):675-86. PubMed ID: 24431073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NEDD4 protects vascular endothelial cells against Angiotensin II-induced cell death via enhancement of XPO1-mediated nuclear export.
    Xu J; Sheng Z; Li F; Wang S; Yuan Y; Wang M; Yu Z
    Exp Cell Res; 2019 Oct; 383(1):111505. PubMed ID: 31326389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The nuclear export protein XPO1 - from biology to targeted therapy.
    Azmi AS; Uddin MH; Mohammad RM
    Nat Rev Clin Oncol; 2021 Mar; 18(3):152-169. PubMed ID: 33173198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Understanding XPO1 target networks using systems biology and mathematical modeling.
    Muqbil I; Kauffman M; Shacham S; Mohammad RM; Azmi AS
    Curr Pharm Des; 2014; 20(1):56-65. PubMed ID: 23530499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia.
    Vercruysse T; De Bie J; Neggers JE; Jacquemyn M; Vanstreels E; Schmid-Burgk JL; Hornung V; Baloglu E; Landesman Y; Senapedis W; Shacham S; Dagklis A; Cools J; Daelemans D
    Clin Cancer Res; 2017 May; 23(10):2528-2541. PubMed ID: 27780859
    [No Abstract]   [Full Text] [Related]  

  • 30. Nuclear Export in Non-Hodgkin Lymphoma and Implications for Targeted XPO1 Inhibitors.
    Trkulja KL; Manji F; Kuruvilla J; Laister RC
    Biomolecules; 2023 Jan; 13(1):. PubMed ID: 36671496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a.
    Wang J; Sun T; Meng Z; Wang L; Li M; Chen J; Qin T; Yu J; Zhang M; Bie Z; Dong Z; Jiang X; Lin L; Zhang C; Liu Z; Jiang R; Yang G; Li L; Zhang Y; Huang D
    Cancer Lett; 2021 Apr; 503():197-212. PubMed ID: 33493586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exportin 1-mediated nuclear/cytoplasmic trafficking controls drug sensitivity of classical Hodgkin's lymphoma.
    Caillot M; Miloudi H; Taly A; Profitós-Pelejà N; Santos JC; Ribeiro ML; Maitre E; Saule S; Roué G; Jardin F; Sola B
    Mol Oncol; 2023 Dec; 17(12):2546-2564. PubMed ID: 36727672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds.
    Crochiere M; Kashyap T; Kalid O; Shechter S; Klebanov B; Senapedis W; Saint-Martin JR; Landesman Y
    BMC Cancer; 2015 Nov; 15():910. PubMed ID: 26573568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma.
    Yoshimura M; Ishizawa J; Ruvolo V; Dilip A; Quintás-Cardama A; McDonnell TJ; Neelapu SS; Kwak LW; Shacham S; Kauffman M; Tabe Y; Yokoo M; Kimura S; Andreeff M; Kojima K
    Cancer Sci; 2014 Jul; 105(7):795-801. PubMed ID: 24766216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents.
    Parikh K; Cang S; Sekhri A; Liu D
    J Hematol Oncol; 2014 Oct; 7():78. PubMed ID: 25316614
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selinexor demonstrates anti-tumor efficacy in paired patient-derived xenograft models and hydrogel-embedded histoculture drug sensitivity test of penile cancer.
    He Y; Mei J; Hao H; Liu F; Yi Y; Hu C; Zou F; Lu X
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):6931-6941. PubMed ID: 36840755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
    Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
    Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nuclear transport proteins: structure, function, and disease relevance.
    Yang Y; Guo L; Chen L; Gong B; Jia D; Sun Q
    Signal Transduct Target Ther; 2023 Nov; 8(1):425. PubMed ID: 37945593
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective Inhibitors of Nuclear Export in the Treatment of Hematologic Malignancies.
    Allegra A; Innao V; Allegra AG; Leanza R; Musolino C
    Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):689-698. PubMed ID: 31543372
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of Novel Covalent XPO1 Inhibitors Based on a Hybrid Virtual Screening Strategy.
    Shen Z; Zhuang W; Li K; Guo Y; Qu B; Chen S; Gao J; Liu J; Xu L; Dong X; Che J; Li Q
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.